ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
39 hedge funds and large institutions have $3.57M invested in ImmunoCellular Therapeutics, Ltd. in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 5 closing their positions.
184% more call options, than puts
Call options by funds: $71K | Put options by funds: $25K
7% less funds holding
Funds holding: 42 → 39 (-3)
21% less capital invested
Capital invested by funds: $4.51M → $3.57M (-$946K)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$213K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$48.4K |
| 3 |
U
UBS
Zurich,
Switzerland
|
+$44.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.1K |
| 5 |
D.E. Shaw & Co
New York
|
+$13.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$119K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$99.5K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$58.6K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$42K |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$25K |
IMUC Hedge Fund Activity: Q3 2014 in Review
39 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q3 2014, worth a combined $3.57M — down 21% from $4.51M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMUC and 2 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $213K. The largest seller was Morgan Stanley, cutting an estimated $119K.
- 39 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q3 2014, down from 42 in Q2 2014.
- Funds reported $3.57M of ImmunoCellular Therapeutics, Ltd. stock for Q3 2014, down 21% quarter-over-quarter.
- 2 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q3 2014 and 5 closed out, a net change of -3 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q3 2014 was Geode Capital Management, an estimated $213K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q3 2014 was Morgan Stanley, an estimated $119K sold.
Based on aggregated 13F filings for Q3 2014.